Document Detail

In vivo effects of defibrotide on platelet c-AMP and blood prostanoid levels.
MedLine Citation:
PMID:  3011617     Owner:  NLM     Status:  MEDLINE    
Patients were treated with defibrotide (3 X 200 mg/day) for 7 days. Plasma PGI2 and TXB2 levels were measured by RIA using EDTA-aspisol as anticoagulant and cyclooxygenase inhibitor. Isolated platelet c-AMP levels were also determined by RIA, using EDTA-dipyridamole as anticoagulant and phosphodiesterase inhibitor. Blood PGI2 levels were found to increase significantly upon treatment while the increase in TXB2 levels was not significant. Blood PGI2/TXB2 ratio increased 51%, 30 min after intravenous injection and it remained 28% higher during therapy than the predrug blood level. Significantly higher platelet c-AMP levels were also obtained after the injection of drug (0.02 less than p less than 0.05).
G Cizmeci
Related Documents :
23399357 - Bio-modulators in platelet-rich plasma: a comparison of the amounts in products from he...
6585847 - The intrainfusion platelet rebound during and following pge1-infusion is faster and mor...
6803307 - Increased platelet activity after termination of prostacyclin infusion into man.
3011617 - In vivo effects of defibrotide on platelet c-amp and blood prostanoid levels.
7847587 - Magnesium deficiency in alcoholism: possible contribution to osteoporosis and cardiovas...
15753897 - Defective production of soluble hla-g molecules by peripheral blood monocytes in patien...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Haemostasis     Volume:  16 Suppl 1     ISSN:  0301-0147     ISO Abbreviation:  Haemostasis     Publication Date:  1986  
Date Detail:
Created Date:  1986-06-30     Completed Date:  1986-06-30     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  0371574     Medline TA:  Haemostasis     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  31-5     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
6-Ketoprostaglandin F1 alpha / blood
Arteriosclerosis / blood*,  drug therapy
Blood Platelets / drug effects*,  metabolism
Cyclic AMP / blood
Fibrinolytic Agents / therapeutic use*
Malondialdehyde / blood
Platelet Aggregation / drug effects
Polydeoxyribonucleotides / therapeutic use*
Prostaglandins / blood*
Thromboxane B2 / blood
Time Factors
Reg. No./Substance:
0/Fibrinolytic Agents; 0/Polydeoxyribonucleotides; 0/Prostaglandins; 438HCF2X0M/defibrotide; 542-78-9/Malondialdehyde; 54397-85-2/Thromboxane B2; 58962-34-8/6-Ketoprostaglandin F1 alpha; 60-92-4/Cyclic AMP

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Beneficial effects of defibrotide against myocardial ischemia and decline of beta-adrenoceptor funct...
Next Document:  [Vasoconstrictor responses of isolated pig coronary arteries].